Researchers used a sophisticated combination of proteomics and metabolomics to show how RCC reprograms its metabolism and evades the immune system.
A recent letter in JCO discusses whether patients with locally advanced rectal cancer need adjuvant chemotherapy.
Common gastrointestinal symptoms experienced by patients with cancer can vary widely and determining an underlying malignancy can prove difficult.
[Biomarkers in Cancer] Cluster of differentiation 151 (CD151) functions at various stages of cancer, including metastatic cascade and primary tumor growth, reinforcing the importance of CD151 as a target in oncology.
From Oncology Nurse Advisor
Post-treatment surveillance linked to improved survival in head and neck squamous cell cancer (HNSCC)
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- CD151—A Striking Marker for Cancer Therapy
- Tumor Infiltrating Lymphocytes Play Prognostic Role in Triple Negative Breast Cancer
- Addition of Levetiracetam May Improve Survival for Glioblastoma
- VCD Regimen Preferable as Induction for Newly Diagnosed Multiple Myeloma
- Multigene Cancer-Susceptibility Tests Require New Approaches to Patient Counseling
- Vitamin D Levels and Risk for Pancreatic Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Nicotinamide Safe, Effective for Non-Melanoma Skin Cancer Prevention in High-Risk Patients
- Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?
- Study Suggests Renal Cell Carcinoma Reprograms its Metabolism to Evade Immune System
- Vismodegib Safe, Effective in Twelve-Month Study Update
- Dovitinib Shows Activity in Advanced Endometrial Cancer
- Chromosomal Instability Associated with Improved Outcomes in Breast Cancer
- Malignant Gastric Outlet Obstruction
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|